Michèle Janine Hoffmann

24PUBLICATIONS
76CO-AUTHORS
Molecular targetsRegenerative medicine (incl. stem cells)Disease surveillanceCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Nov 11, 2025
Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.

Jutta Schmitz, Anna L Bartkowiak, Michael Rose

|Jun 26, 2025
BMP-2-Driven Osteogenesis: A Comparative Analysis of Porcine BMSCs and ASCs and the Role of TGF-β and FGF Signaling.

Roman Taday, Pascal Jungbluth, Sebastian Zensen

|May 12, 2025
Repurposing Amiodarone for Bladder Cancer Treatment.

Francisco J Roa, Maria Roubelakis, Konstantinos Paschidis

|May 02, 2024
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.

Sarah Meneceur, Caroline E De Vos, Patrick Petzsch

|Sep 23, 2022
Differential DNA Methylation of THOR and hTAPAS in the Regulation of hTERT and the Diagnosis of Cancer.

Pauline Ott, Marcos J Araúzo-Bravo, Michèle J Hoffmann

|Aug 24, 2022
Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies.

Aaron Burmeister, Alexa Stephan, Leandro A Alves Avelar

Pageof 4

Frequent Collaborators

14 joint publications

Günter Niegisch

11 joint publications

Wolfgang A Schulz

8 joint publications

Patrick Petzsch

7 joint publications

Karl Köhrer